Role the yap-1 transcriptional target ciap2 in the differential susceptibility to chemotherapy non-small-cell lung cancer (nsclc) patients with tumor rassf1a gene methylation from the phase ifct-0002 trial

HIGHLIGHTS

• who: Virginie Westeel et al. from the Department Pathology, CHU Caen, Caen, France Department Pneumology, University Hospital Besançon, University Bourgogne Franche-Comté have published the paper: Role the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase IFCT-0002 Trial, in the Journal: (JOURNAL)
• what: This study reports herein that gemcitabine synergizes with RASSF1A silencing to increase the IAP-2 expression which in turn not only interferes with cell proliferation but also promotes cell migration. By using . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.